Scott And White Memorial Hospital
- Type
- Teaching hospital
- Where
- Temple, TX
- Medicare CCN
- 450054
- Received
- $415,832 in 129 records, 2020 ($58,007 general, $357,825 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: SCOTT & WHITE MEMORIAL HOSPITAL Fuzzy (name and state)
- Nonprofit contractor: Scott & White Memorial Hospital Fuzzy (name and state)
- Federal award recipient: SCOTT & WHITE MEMORIAL HOSPITAL Fuzzy (name and state)
- Nonprofit: SCOTT & WHITE MEMORIAL HOSPITAL Fuzzy (name and state)
- Patent assignee: Scott & White Memorial Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 21 | $58,007 |
| 2020 | Research payment | 108 | $357,825 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | 1 | $127,029 | 2020 |
| PFIZER INC. | 1 | $37,659 | 2020 |
| Celgene Corporation | 3 | $33,705 | 2020 |
| Stryker Corporation | 2 | $30,890 | 2020 |
| Premia Spine, Ltd. | 8 | $23,980 | 2020 |
| Incyte Corporation | 36 | $21,430 | 2020 |
| Actelion Pharmaceuticals, Ltd | 9 | $18,432 | 2020 |
| TerSera Therapeutics LLC | 4 | $17,632 | 2020 |
| Siemens Medical Solutions USA, Inc. | 4 | $16,970 | 2020 |
| Acerta Pharma LLC | 1 | $15,387 | 2020 |
| UCB Biosciences Inc. | 2 | $14,870 | 2020 |
| LeMaitre Vascular, Inc. | 1 | $14,099 | 2020 |
| GlaxoSmithKline, LLC. | 9 | $12,130 | 2020 |
| Mentor Worldwide LLC | 19 | $6,590 | 2020 |
| Masimo Corporation | 6 | $6,078 | 2020 |
| Aesculap, Inc. | 4 | $5,464 | 2020 |
| GE HEALTHCARE | 1 | $5,050 | 2020 |
| Genentech, Inc. | 4 | $2,845 | 2020 |
| Merck Sharp & Dohme LLC | 4 | $1,738 | 2020 |
| ABBVIE INC. | 4 | $1,556 | 2020 |
| Vitrolife Inc. | 1 | $965 | 2020 |
| Aesculap Implant Systems, LLC | 1 | $896 | 2020 |
| Abbott Laboratories | 1 | $269 | 2020 |
| Cook Research Incorporated | 1 | $100 | 2020 |
| Zimmer Biomet Holdings, Inc. | 1 | $37 | 2020 |
| Olympus America Inc. | 1 | $22 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 108 | $357,825 |
| Gift | 10 | $43,587 |
| Education | 6 | $6,078 |
| Charitable Contribution | 3 | $5,251 |
| Grant | 1 | $2,820 |
| Space rental or facility fees (teaching hospital only) | 1 | $269 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Stryker Corporation | $22,102 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | LeMaitre Vascular, Inc. | $14,099 | Gift | Cash or cash equivalent | TRIVEX Device, TRIVEX | 2020 | |
| 2020-12-31 | Masimo Corporation | $2,988 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $2,820 | Grant | Cash or cash equivalent | SOMATOM GO Device, CT and RO incl. Computed Tomography and Radiation Oncology | 2020 | |
| 2020-12-31 | Masimo Corporation | $1,127 | Education | In-kind items and services | Patient SafetyNet System Device, Devices | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $174 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-31 | Zimmer Biomet Holdings, Inc. | $37 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $26 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-17 | TerSera Therapeutics LLC | $187 | Research payment | Cash or cash equivalent | QUZYTTIR Drug, ACUTE CARE | A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Preventi | 2020 |
| 2020-12-16 | Celgene Corporation | $3,475 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Celgene - Connect MDS/AML | 2020 |
| 2020-12-11 | Aesculap Implant Systems, LLC | $896 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $1,618 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $1,618 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $1,618 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $609 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 | |
| 2020-11-18 | Mentor Worldwide LLC | $180 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-11-13 | JAZZ PHARMACEUTICALS INC. | $127,029 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2020 |
| 2020-11-04 | Premia Spine, Ltd. | $2,684 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2020 |
| 2020-11-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 | |
| 2020-10-14 | Mentor Worldwide LLC | $250 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-10-08 | Incyte Corporation | $1,650 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-10-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 | |
| 2020-09-29 | Merck Sharp & Dohme LLC | $250 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab MK-3475 plus Binimetinib alone or the Combination of P | 2020 |
| 2020-09-28 | Actelion Pharmaceuticals, Ltd | $500 | Research payment | Cash or cash equivalent | OPsumit Users Registry | 2020 | |
| 2020-09-28 | Actelion Pharmaceuticals, Ltd | $300 | Research payment | Cash or cash equivalent | OPsumit Users Registry | 2020 | |
| 2020-09-08 | Actelion Pharmaceuticals, Ltd | $500 | Research payment | Cash or cash equivalent | OPsumit Users Registry | 2020 | |
| 2020-09-08 | Actelion Pharmaceuticals, Ltd | $500 | Research payment | Cash or cash equivalent | OPsumit Users Registry | 2020 | |
| 2020-09-08 | Actelion Pharmaceuticals, Ltd | $500 | Research payment | Cash or cash equivalent | OPsumit Users Registry | 2020 | |
| 2020-09-08 | Actelion Pharmaceuticals, Ltd | $300 | Research payment | Cash or cash equivalent | OPsumit Users Registry | 2020 | |
| 2020-09-08 | Actelion Pharmaceuticals, Ltd | $300 | Research payment | Cash or cash equivalent | OPsumit Users Registry | 2020 | |
| 2020-09-08 | Actelion Pharmaceuticals, Ltd | $150 | Research payment | Cash or cash equivalent | OPsumit Users Registry | 2020 | |
| 2020-09-03 | Premia Spine, Ltd. | $4,491 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2020 |
| 2020-09-03 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-282 | 2020 |
| 2020-09-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 | |
| 2020-08-20 | GlaxoSmithKline, LLC. | $1,400 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2020 |
| 2020-08-20 | GlaxoSmithKline, LLC. | $455 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2020 |
| 2020-08-17 | Incyte Corporation | $1,258 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-08-12 | Mentor Worldwide LLC | $180 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-08-10 | Incyte Corporation | $32 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $32 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $16 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $15 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $15 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $14 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $14 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $14 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $14 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $14 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $9 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $9 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-10 | Incyte Corporation | $9 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-08-08 | Merck Sharp & Dohme LLC | $930 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab MK-3475 plus Binimetinib alone or the Combination of P | 2020 |
| 2020-08-07 | Mentor Worldwide LLC | $906 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-08-06 | Celgene Corporation | $19,750 | Research payment | Cash or cash equivalent | Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | 2020 | |
| 2020-08-03 | TerSera Therapeutics LLC | $97 | Research payment | Cash or cash equivalent | QUZYTTIR Drug, ACUTE CARE | A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Preventi | 2020 |
| 2020-08-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 | |
| 2020-07-29 | ABBVIE INC. | $556 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P10-262 | 2020 |
| 2020-07-29 | Abbott Laboratories | $269 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-07-29 | Mentor Worldwide LLC | $250 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-07-15 | Premia Spine, Ltd. | $6,298 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2020 |
| 2020-07-15 | Mentor Worldwide LLC | $180 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-07-15 | Mentor Worldwide LLC | $55 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-07-08 | Mentor Worldwide LLC | $578 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-07-08 | Mentor Worldwide LLC | $578 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-07-07 | Incyte Corporation | $4,108 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-07-06 | Actelion Pharmaceuticals, Ltd | $15,382 | Research payment | Cash or cash equivalent | OPsumit Users Registry | 2020 | |
| 2020-07-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 | |
| 2020-06-17 | Incyte Corporation | $1,584 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-06-16 | GlaxoSmithKline, LLC. | $455 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2020 |
| 2020-06-12 | Siemens Medical Solutions USA, Inc. | $13,950 | Research payment | Cash or cash equivalent | ADVIA Immunoassay Reagents/Test Kit/Clinical Utilization Device, DX - Diagnostics incl. all products and services | US Evaluation of the ADVIA Centaur CP HBsAgll Assay | 2020 |
| 2020-06-10 | Mentor Worldwide LLC | $578 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-06-04 | Premia Spine, Ltd. | $1,000 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2020 |
| 2020-06-04 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-282 | 2020 |
| 2020-06-03 | Incyte Corporation | $2,300 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-06-03 | Mentor Worldwide LLC | $1,000 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-06-03 | Mentor Worldwide LLC | $250 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-06-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 | |
| 2020-05-20 | Incyte Corporation | $1,555 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-05-14 | Premia Spine, Ltd. | $250 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2020 |
| 2020-05-06 | Mentor Worldwide LLC | $250 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-05-05 | Premia Spine, Ltd. | $1,975 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2020 |
| 2020-05-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 | |
| 2020-04-27 | Vitrolife Inc. | $965 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-04-20 | Genentech, Inc. | $1,345 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PERTAIN PERTU TRASTU AI 1ST LINE HER2 MBC | 2020 |
| 2020-04-16 | Incyte Corporation | $1,728 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-04-16 | Incyte Corporation | $1,531 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-04-16 | Incyte Corporation | $1,364 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-04-16 | Incyte Corporation | $1,123 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-04-13 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PERTAIN PERTU TRASTU AI 1ST LINE HER2 MBC | 2020 |
| 2020-04-09 | GlaxoSmithKline, LLC. | $430 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2020 |
| 2020-04-08 | TerSera Therapeutics LLC | $474 | Research payment | Cash or cash equivalent | QUZYTTIR Drug, ACUTE CARE | A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Preventi | 2020 |
| 2020-04-08 | Mentor Worldwide LLC | $180 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-04-08 | Mentor Worldwide LLC | $180 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-04-08 | Mentor Worldwide LLC | $180 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-04-08 | Mentor Worldwide LLC | $180 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-04-01 | Incyte Corporation | $1,874 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-04-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 | |
| 2020-03-19 | TerSera Therapeutics LLC | $16,873 | Research payment | Cash or cash equivalent | QUZYTTIR Drug, ACUTE CARE | A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Preventi | 2020 |
| 2020-03-19 | Merck Sharp & Dohme LLC | $474 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab MK-3475 plus Binimetinib alone or the Combination of P | 2020 |
| 2020-03-17 | GlaxoSmithKline, LLC. | $4,550 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2020 |
| 2020-03-16 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PERTAIN PERTU TRASTU AI 1ST LINE HER2 MBC | 2020 |
| 2020-03-16 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PERTAIN PERTU TRASTU AI 1ST LINE HER2 MBC | 2020 |
| 2020-03-12 | GlaxoSmithKline, LLC. | $500 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2020 |
| 2020-03-10 | Mentor Worldwide LLC | $578 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-03-10 | Masimo Corporation | $31 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-03-06 | GlaxoSmithKline, LLC. | $750 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2020 |
| 2020-03-04 | Premia Spine, Ltd. | $5,804 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2020 |
| 2020-03-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 | |
| 2020-02-29 | Masimo Corporation | $1,659 | Education | In-kind items and services | Patient SafetyNet System Device, Devices | 2020 | |
| 2020-02-29 | Masimo Corporation | $225 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-02-29 | Masimo Corporation | $46 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-02-21 | Cook Research Incorporated | $100 | Research payment | Cash or cash equivalent | Cook Medical Thoracic Device, Aortic Intervention | (11-007) Use of the Zenith Dissection Endovascular System in the Treatment of Patients with Acute, Complicated Type B Ao | 2020 |
| 2020-02-14 | GlaxoSmithKline, LLC. | $1,795 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2020 |
| 2020-02-11 | Celgene Corporation | $10,480 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Celgene - Connect MM | 2020 |
| 2020-02-06 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-282 | 2020 |
| 2020-02-04 | Premia Spine, Ltd. | $1,475 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2020 |
| 2020-02-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 | |
| 2020-01-31 | GE HEALTHCARE | $5,050 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-01-28 | Olympus America Inc. | $22 | Gift | In-kind items and services | Olympus Capital Accessories Device, GI & Respiratory Products | 2020 | |
| 2020-01-24 | Merck Sharp & Dohme LLC | $83 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab MK-3475 plus Binimetinib alone or the Combination of P | 2020 |
| 2020-01-21 | Stryker Corporation | $8,788 | Research payment | Cash or cash equivalent | MESA RAIL Device, SPINE | MESA RAIL AIS STUDY - PRESERVATION OF CURVE CORRECTION | 2020 |
| 2020-01-20 | UCB Biosciences Inc. | $11,100 | Research payment | Cash or cash equivalent | Cimzia Drug, Immunology | A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol CIMZIA For Crohn's | 2020 |
| 2020-01-20 | UCB Biosciences Inc. | $3,769 | Research payment | Cash or cash equivalent | Cimzia Drug, Immunology | A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol CIMZIA For Crohn's | 2020 |
| 2020-01-15 | PFIZER INC. | $37,659 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 | 2020 | |
| 2020-01-15 | Mentor Worldwide LLC | $55 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjec | 2020 |
| 2020-01-02 | Acerta Pharma LLC | $15,387 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated | 2020 |
| 2020-01-02 | GlaxoSmithKline, LLC. | $1,795 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2020 |
| 2020-01-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Temple, TX, county Bell County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Temple, TX | County Bell County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 89,602 | 386,897 | 30,188,424 |
| Population, 2020 census P1 | 82,073 | 370,647 | 29,145,505 |
| Median age B01002 | 33.8 | 32.3 | 35.6 |
| Under 18 B01001 | 26.6% | 27.5% | 25.0% |
| 65 and over B01001 | 15.1% | 11.9% | 13.4% |
| Households B11001 | 34,514 | 142,305 | 10,992,816 |
| Foreign born B05002 | 8.2% | 8.6% | 17.6% |
| Median household income B19013 | $68,204 | $68,865 | $78,476 |
| Median family income B19113 | $86,005 | $81,043 | $94,599 |
| Per capita income B19301 | $34,319 | $34,279 | $40,752 |
| Poverty rate B17001 | 16.0% | 14.5% | 13.8% |
| Unemployment rate B23025 | 6.6% | 6.8% | 5.3% |
| Civilian labor force B23025 | 42,457 | 170,572 | 15,233,563 |
| Mean commute (minutes) B08013 | 21.0 | 23.9 | 26.7 |
| Bachelor's degree or higher B15003 | 30.6% | 27.2% | 33.8% |
| Housing units B25001 | 37,299 | 155,018 | 12,128,515 |
| Owner-occupied B25003 | 52.3% | 56.5% | 62.6% |
| Renters B25003 | 47.7% | 43.5% | 37.4% |
| Median home value B25077 | $239,000 | $241,000 | $283,800 |
| Median gross rent B25064 | $1,231 | $1,224 | $1,403 |
| White, not Hispanic B03002 | 51.4% | 42.4% | 39.1% |
| Black B03002 | 12.1% | 21.5% | 11.9% |
| Hispanic or Latino B03002 | 29.0% | 26.3% | 39.7% |
| Asian B03002 | 2.0% | 2.9% | 5.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Temple, TX.
Comments